Unveiling Mavenclad’s Remarkable Benefits: Sustained Efficacy in MS
EMD Serono presented data at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, showcasing the...
Jon Napitupulu
Sanofi, Radiomedix, and OranoMed Sign Revolutionary Licensing Agreement for Next-Gen Radioligand Medicine
Sanofi, RadioMedix, and Orano Med have partnered to advance AlphaMedixTM, a treatment for a rare cancer known as neuroendocrine...
Cancer Therapies Revolutionized: Tetraspecific Antibodies Promise Breakthroughs in 2029
The biomedical field is witnessing a groundbreaking era with the advent of tetraspecific antibodies. These antibodies, representing the next...
Genesis & Gilead: A Novel Discovery Together
Gilead Sciences and Genesis Therapeutics have formed a collaboration to develop novel therapies through generative AI technology. Genesis’ GEMS...
AiCure H.code Patient Engagement Platform Unveiled at dpharm 2024
AiCure, a pioneer in clinical trial monitoring and patient engagement, will debut its innovative H.Code platform at the DPHARM...
Aditxt and Evofem Secure Merger to Empower Women’s Health
Aditxt and Evofem Biosciences have agreed to merge, creating an alliance focused on accelerating health innovations in women’s healthcare....
Silexion Therapeutics Unveils Pioneering RNAi Technology from Silexion Therapeutics for Revolutionizing the Fight Against KRAS-Driven Cancers
Silexion’s proprietary LODER™ platform enables targeted oncogene silencing, using siRNA to block the production of oncogenic proteins. This approach...
Innate Pharma’s Monalizumab NeoCOAST-2 Phase 2 Trial Reports Encouraging Outcomes in Early-Stage Lung Cancer
The NeoCOAST-2 trial evaluated the efficacy and safety of treatments in patients with early-stage non-small cell lung cancersmall cell...
AstraZeneca TROP2 Biomarker Predicts Lung Cancer Treatment Outcomes
An exploratory analysis of the TROPION-Lung01 phase 3 trial revealed TROP2 expression, measured using AstraZeneca’s computational pathology platform, as...
Summit Therapeutics’s Remarkable Cancer Breakthrough: New Treatment Reduces Disease Progression by 49%
Summit Therapeutics and Akeso announced positive results from the Phase III HARMONi-2 trial, evaluating ivonescimab, an investigational bispecific antibody,...